ArticleBMC pulmonary medicine2010
beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells.
Article in BMC pulmonary medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Is the SPLUNC1-Orai1 axis a critical determinant of lung health?Biochemical Society transactions · 2025Review
- In vitro modelling of bacterial pneumonia: a comparative analysis of widely applied complex cell culture models.FEMS microbiology reviews · 2024Review
- Metabolism Characteristics ofAllergy, asthma & immunology research · 2022Article
- Review
- Article
- The effect of BPIFA1/SPLUNC1 genetic variation on its expression and function in asthmatic airway epithelium.JCI insight · 2019Article
- BPIFA1 regulates lung neutrophil recruitment and interferon signaling during acute inflammation.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Immunoproteasomes as a novel antiviral mechanism in rhinovirus-infected airways.Clinical science (London, England : 1979) · 2018Article
- Overproduction of growth differentiation factor 15 promotes human rhinovirus infection and virus-induced inflammation in the lung.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia.Frontiers in immunology · 2018Review
- Mycoplasma pneumoniae from the Respiratory Tract and Beyond.Clinical microbiology reviews · 2017Review
- Identification of BPIFA1/SPLUNC1 as an epithelium-derived smooth muscle relaxing factor.Nature communications · 2017Article
- The Anti-inflammatory Effect of Alpha-1 Antitrypsin in Rhinovirus-infected Human Airway Epithelial Cells.Journal of clinical & cellular immunology · 2016Article
- α1-Antitrypsin reduces rhinovirus infection in primary human airway epithelial cells exposed to cigarette smoke.International journal of chronic obstructive pulmonary disease · 2016Article
- Bactericidal/Permeability-increasing protein fold-containing family member A1 in airway host protection and respiratory disease.American journal of respiratory cell and molecular biology · 2015Review
- Adrenergic regulation of innate immunity: a review.Frontiers in pharmacology · 2015Review
- Decreased PLUNC expression in nasal polyps is associated with multibacterial colonization in chronic rhinosinusitis patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2014Article
- Electronic cigarette liquid increases inflammation and virus infection in primary human airway epithelial cells.PloS one · 2014Article
- Response of Differentiated Human Airway Epithelia to Alcohol Exposure andMedical sciences (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAirway epithelial cells are critical in host defense against bacteria including Mycoplasma pneumoniae (Mp) in chronic obstructive pulmonary disease (COPD) and asthma. beta2-agonists are mainstay of COPD and asthma therapy, but whether beta2-agonists directly affect airway epithelial host defense functions is unclear.
methodsEpithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and COPD (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (CSE) and/or Th2 cytokine IL-13, followed by Mp infection and treatment with beta2-agonists albuterol and formoterol for up to seven days. Mp and host defense proteins short palate, lung, and nasal epithelial clone 1 (SPLUNC1) and beta-defensin-2 were quantified. Expression of beta2-adrenergic receptors was also measured by real-time quantitative RT-PCR.
results(R)- or racemic albuterol and (R,R)- or racemic formoterol significantly decreased Mp levels in normal and asthma epithelial cells. Normal cells treated with Mp and (R)- or racemic albuterol showed an increase in SPLUNC1, but not in beta-defensin-2. COPD cells did not respond to drug treatment with a significant decrease in Mp or an increase in SPLUNC1. IL-13 attenuated drug effects on Mp, and markedly decreased SPLUNC1 and beta2-adrenergic receptors.
conclusionsThese results for the first time show that beta2-agonists enhance host defense functions of primary bronchial epithelial cells from normal and asthma subjects, which is attenuated by IL-13.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.